

CLEAN VERSION OF PENDING CLAIMS

- A 2
34. [Amended] A polypeptide comprising a lysosomal enzyme, a naturally secreted protein, a nuclear protein, or a cytoplasmic protein operably linked to a PTD, wherein the polypeptide is expressed from an expression vector located *in situ* in a brain cell of a patient, and wherein the polypeptide is biologically active.
35. The polypeptide of claim 34, wherein the polypeptide is a lysosomal enzyme.
36. The polypeptide of claim 34, wherein the lysosomal enzyme is a soluble lysosomal enzyme.
37. The polypeptide of claim 36, wherein the soluble lysosomal enzyme is β -glucuronidase, pepstatin insensitive protease or palmitoyl protein thioesterase.
- A 3
38. [Amended] The polypeptide of claim 36, wherein the soluble lysosomal enzyme is β -glucuronidase.
39. The polypeptide of claim 34, wherein the polypeptide is a secreted protein.
40. The polypeptide of claim 39, wherein the secreted protein is a growth factor or an anti-neoplastic protein.
41. The polypeptide of claim 40, wherein the growth factor is GDNF, NGF, BDNF, or NT3.
42. The polypeptide of claim 40, wherein the anti-neoplastic protein is an inhibitor of neovascularization, cell migration, or cell proliferation.

43. The polypeptide of claim 34, wherein the polypeptide is a nuclear protein.
44. The polypeptide of claim 43, wherein the nuclear protein is a transcription factor.
45. The polypeptide of claim 34, wherein the polypeptide is a cytoplasmic protein.
46. The polypeptide of claim 45, wherein the cytoplasmic protein is a cytotoxic agent.
47. The polypeptide of claim 34, wherein the PTD is Tat PTD.
48. The polypeptide of claim 47, wherein the Tat PTD is Tat₄₇₋₅₇.
62. [New] The polypeptide of claim 34, wherein the polypeptide is enzymatically active.